A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Part of paid clinical trials in Daphne, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07361510
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pumitamig — DRUGSpecified dose on specified days
- Pembrolizumab — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Key Dates
- Start date
- Mar 12, 2026
- Status verified
- Jun 2026
- Primary completion
- Oct 14, 2031
- Completion
- Oct 14, 2031
Study Design
- Enrollment
- 750 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Pumitamig
- Active Comparator: Arm B: Pembrolizumab
Primary Outcome Measure
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Up to approximately 3 years ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (40)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Southern Cancer Center Pc | Daphne | Alabama | 36526 | Michael Meshad, Site 0348 111-111-1111 |
| Local Institution - 0424 | Bullhead City | Arizona | 86442 | Site 0424 |
| Local Institution - 0391 | Glendale | Arizona | 85304 | Site 0391 |
| Local Institution - 0407 | Anaheim | California | 92801 | Site 0407 |
| Local Institution - 0352 | Beverly Hills | California | 90211 | Site 0352 |
| Orange Coast Memorial Medical Center | Fountain Valley | California | 92708 | Amol Rao, Site 0299 510673-1293 |
| Local Institution - 0027 | Los Alamitos | California | 90720 | Site 0027 |
| Local Institution - 0422 | Los Angeles | California | 90095 | Site 0422 |
| Local Institution - 0403 | Oakland | California | 94611 | Site 0403 |
| Local Institution - 0208 | Pleasant Hill | California | 94523 | Site 0208 |
| Local Institution - 0416 | Walnut Creek | California | 94598 | Site 0416 |
| Local Institution - 0340 | Lakewood | Colorado | 80401 | Site 0340 |
| Clermont Oncology Center | Clermont | Florida | 34711 | Gopal Kunta, Site 0192 352-242-1366 |
| Advanced Research | Coral Springs | Florida | 33321 | Sumit Sawhney, Site 0406 954-302-3120 |
| BRP- Hialeah Hospital | Hialeah | Florida | 33013 | Luis Rangel, Site 0395 833-489-4968 |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | Frederick Flynt Jr, Site 0396 706-353-2990 |
| Local Institution - 0412 | Augusta | Georgia | 30912 | Site 0412 |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta | Georgia | 30060 | Walid Shaib, Site 0284 770-281-5124 |
| Local Institution - 0423 | Urbana | Illinois | 61801 | Site 0423 |
| Northwest Cancer Centers, P.C. | Dyer | Indiana | 46311 | Shruti Singh, Site 0409 219-924-8178 |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | Caleb Smith, Site 0350 |
| Local Institution - 0224 | Laurelton | New York | 11413 | Site 0224 |
| Local Institution - 0026 | New York | New York | 10065 | Site 0026 |
| Local Institution - 0214 | Westbury | New York | 11590 | Site 0214 |
| Local Institution - 0283 | Winston-Salem | North Carolina | 27103 | Site 0283 |
| Local Institution - 0383 | Cincinnati | Ohio | 45220 | Site 0383 |
| Local Institution - 0418 | Oklahoma City | Oklahoma | 73109 | Site 0418 |
| Local Institution - 0288 | Lancaster | Pennsylvania | 17601 | Site 0288 |
| Local Institution - 0028 | Pittsburgh | Pennsylvania | 15212 | Site 0028 |
| WellSpan Oncology Research | York | Pennsylvania | 17403 | Ikechukwu Akunyili, Site 0344 717-339-2560 |
| Local Institution - 0376 | Galveston | Texas | 77555 | Site 0376 |
| Kelsey-Seybold Clinic Main Campus | Houston | Texas | 77025 | Sunil Patel, Site 0353 713-442-1700 |
| Local Institution - 0381 | San Antonio | Texas | 78260 | Site 0381 |
| Texas Oncology - San Antonio | San Antonio | Texas | 78217 | Krishna Alluri, Site 0351 210-656-7177 |
| Local Institution - 0337 | Richmond | Virginia | 23298 | Site 0337 |
| Shenandoah Oncology, P.C. | Winchester | Virginia | 22601 | Michael McCusker Jr., Site 0349 |
| Local Institution - 0384 | Spokane | Washington | 99218 | Site 0384 |
| Local Institution - 0339 | Charleston | West Virginia | 25304 | Site 0339 |
| Local Institution - 0380 | Green Bay | Wisconsin | 54301 | Site 0380 |
| Local Institution - 0421 | Marshfield | Wisconsin | 54449 | Site 0421 |
Find similar trials in Daphne, AL
Related Studies
- Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung CancerPHASE1/PHASE2 · Recruiting · Olivera Finn · Pittsburgh, Pennsylvania
- ROSE for Improved Molecular Marker Testing Via EBUSEnrolling By Invitation · Johns Hopkins University · Chicago, Illinois
- A Study of NX-1607 in Adults With Advanced MalignanciesPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Duarte, California
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona